Tata India Pharma & Healthcare Fund - Growth - Direct Plan

Other Plans and Options
  • 0.63 %Nav, as on 31-03-2023

  • Previous Nav

  • Net Change on 31-03-2023

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview Growth | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

Investment objective of the scheme is to provide long term capital appreciation by investing predominantly in equity/equity related instruments of the companies in the Pharma&Healthcare sectors in India. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
Tata India Pharma & Healthcare Fund-Direct Plan-Growth 1.51 -3.77 -6.14 22.99 15.53 8.31
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
NIFTY PHARMA - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Tata India Pharma & Healthcare Fund-Direct Plan-Growth Dec 28, 2015 -6.14 22.99 15.53 1.01 485.91
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - Growth Jan 01, 2013 -5.89 24.71 16.16 1.26 4,267.60
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH Jan 01, 2013 -0.89 25.46 14.28 1.09 1,574.52
UTI Healthcare Fund - Direct Plan - Growth Option Jan 01, 2013 -7.66 22.71 12.89 1.50 655.16

Fund Holdings as on 28-February-2023

  • SUN PHARMACEUTICAL INDUSTRIES LTD

  • CIPLA LTD

  • DR REDDYs LABORATORIES LTD

  • LUPIN LTD

  • ALKEM LABORATORIES LTD

  • IPCA LABORATORIES LTD

  • FORTIS HEALTHCARE LTD

  • DIVI LABORATORIES LTD

  • APOLLO HOSPITALS ENTERPRISE LTD

  • HEALTHCARE GLOBAL ENTERPRISES LTD

  • FDC LTD

  • AUROBINDO PHARMA LTD

  • ABBOTT INDIA LTD

  • INDOCO REMEDIES LTD

  • KRISHNA INSTITUTE OF MEDICAL SCIENCES LTD

  • ZYDUS LIFESCIENCES LTD

  • GLAND PHARMA LTD

  • PROCTER & GAMBLE HEALTH LTD

  • GLENMARK PHARMACEUTICALS LTD

  • ASTER DM HEALTHCARE LTD

  • AJANTA PHARMA LTD

  • MEDPLUS HEALTH SERVICES LTD

  • TORRENT PHARMACEUTICALS LTD

  • CASH / NET CURRENT ASSET

  • NARAYANA HRUDAYALAYA LTD

  • GLAXOSMITHKLINE PHARMACEUTICALS LTD

  • A) REPO

  • SANOFI INDIA LTD

  • J.B.CHEMICALS & PHARMACEUTICALS LTD

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Miscellaneous

View More

  • Cash

  • Equity

View More

About Tata India Pharma & Healthcare Fund

Scheme Analysis

Tata India Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to Tata Mutual Fund. It was launched on 28-Dec-2015 and currently has an AUM of ₹485.91 crore. Tata India Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and NIFTY PHARMA - TRI as secondary index.

The NAV of Tata India Pharma & Healthcare Fund ended up ₹0.11(0.63%)yesterday to ₹17.856.

Among its top 3 holdings the fund has exposure to SUN PHARMACEUTICAL INDUSTRIES LTD, and

The Tata India Pharma & Healthcare Fund is managed by Meeta Shetty .

Fund House Contact

1903, B Wing, Parinee Crescenzo, G Block, Bandra Kurla Complex, Bandra East, Mumbai - 400 051

+91 (22) 66578282
kiran@tataamc.com
+91 (22) 22613782